NLS Pharmaceutics (NLSP) and Kadimastem announced an update regarding the proposed merger. On October 21, NLS received an approval letter from the Nasdaq Listing Center for the listing of its common shares and the trading of the company on the Nasdaq Capital Market after completion of the Merger, under NLS’s new name, NewcelX Ltd., with its new trading symbol for its common shares, (NCEL). Accordingly, the closing of the merger is expected to close on October 30 with the transition to trading under the combined company’s new name beginning October 31, subject to fulfillment of the remaining customary closing conditions.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NLSP:
- NLS Pharmaceutics Announces Strategic Merger with Kadimastem
- NLS Pharmaceutics Shareholders Approve Merger with Kadimastem
- Closing Bell Movers: Oracle ticks higher as Trump rescues TikTok in US
- NLS Pharmaceutics files to sell 5M common shares for holders
- NLS Pharmaceutics Engages New Accounting Firm After Marcum’s Resignation